Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

@article{Callander2018TreatmentOC,
  title={Treatment of clinically amyopathic dermatomyositis in adults: a systematic review},
  author={Jenny Anne Callander and Y. Robson and John Ingram and Virginie Piguet},
  journal={British Journal of Dermatology},
  year={2018},
  volume={179}
}
Clinically amyopathic dermatomyositis (CADM) affects a subset of 5–20% of patients with dermatomyositis and is defined as the presence of cutaneous features of dermatomyositis without clinical muscle weakness for ≥ 6 months. There is no consensus on first‐line treatment for CADM and whether treatment should differ from treatment of classic dermatomyositis with muscle weakness. We carried out a systematic review of published literature about treatment of adult patients with CADM, via the Embase… Expand
Treatment challenges in clinically amyopathic dermatomyositis: A case series and review of new therapeutic options for skin involvement
TLDR
The available therapeutic options for skin manifestations in this type of DM are described, and a step‐by‐step therapeutic scheme, using the cutaneous dermatomyositis disease area and severity index to assess response is proposed. Expand
Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?
TLDR
In this issue of the BJD, three articles on the current understanding of the pathogenesis and management of dermatomyositis are assembled and shed new light on both disease mechanisms and therapy for clinicians involved in the management of patients with dermatomyposis and clinically amyopathic dermatomyotis. Expand
Recent Advances in Pharmacological Treatments of Adult Dermatomyositis
TLDR
This review discusses recent studies evaluating efficacy of conventional treatments for clinically amyopathic DM, DM-associated interstitial lung (ILD) disease, and classic DM (CDM). Expand
Dermatomyositis requires long‐term treatment with combined immunosuppressive and immunoglobulin therapy
TLDR
Evaluating data from 15 DM patients treated with immunosuppressants and IVIG and report their long-term follow-up data on muscular and skin symptoms using standardized assessment tools found that eleven patients experienced at least moderate improvement of their muscular strength after only one IVIG cycle and creatine kinase levels reached normal values after four treatment cycles. Expand
Dermatomyositis: An Update on Diagnosis and Treatment
TLDR
Diagnosis is discussed, with a focus on myositis-specific antibodies and their associated phenotypes, and therapies available for this often refractory skin disease are reviewed. Expand
Dermatomyositis Part 2: Diagnosis and Treatment.
TLDR
This review emphasizes the emerging role of myositis specific antibodies (MSAs) in the diagnosis of DM and highlights how MSAs can be used to guide the appropriate work-up for malignancy and interstitial lung disease. Expand
Clinical improvement of a patient with both amyopathic dermatomyositis and psoriasis following treatment with cyclosporine.
TLDR
A case of a 45-year-old woman with both CADM and psoriasis whose lesions were resistant to multiple therapies; she eventually achieved disease control and remission with cyclosporine. Expand
Amyopathic Dermatomyositis (Anti-MDA 5 disease) with pulmonary fibrosis and features of lupus, without evidence of malignancy: A case report
TLDR
Amyopathic Dermatomyositis has a higher incidence of rapidly progressive pulmonary fibrosis, and significant overlap with other rheumatological conditions such as Lupus (SLE) and auto-immune hepatitis, as seen here. Expand
Clinically Amyopathic Dermatomyositis Caused by a Tattoo
TLDR
The CADM induced by a tattoo was first reported, however, further studies are still needed to approach the specific substances within the tattoo that trigger immune response. Expand
Association of antinuclear antibody status with clinical features and malignancy risk in adult‐onset dermatomyositis
TLDR
In patients with adult‐onset DM, ANA negativity is associated with increased likelihood of development of malignancy within 3 years of diagnosis of their DM and Particularly close follow‐up and frequent malignancies screening may be warranted in ANA− individuals with DM. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 114 REFERENCES
Dermatomyositis: a dermatology-based case series.
TLDR
Patients with dermatomyositis in this series had less active myositis at presentation, but were otherwise similar to patients with dermatomeositis/polymyositis previously reported. Expand
Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis
TLDR
It is suggested that patients diagnosed with this syndrome are at risk for fatal interstitial lung disease, malignancy, and/or delayed onset of DM or CCLE and the term dermatomyositis-like skin disease is proposed as a better designation than amyopathic dermatomyposis to describe this distinctive subset of cutaneous symptoms. Expand
Amyopathic dermatomyositis: retrospective review of 37 cases.
TLDR
In most patients, amyopathic dermatomyositis does not progress to myopathy, and prognosis appears favorable, but malignancy may develop. Expand
Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature.
TLDR
Six patients with the classic cutaneous findings of dermatomyositis who did not develop clinical or laboratory evidence of muscle disease for at least 2 years after onset of their skin manifestations are reported, challenging the commonly held notion that muscle disease always develops within 2 years of onset of skin disease. Expand
Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
TLDR
It is suggested that a significant subgroup of patients whose skin lesions have been unresponsive to a single antimalarial benefit from combination therapy with hydroxychloroquine and quinacrine or chloroquines and quInacrine, but controlled clinical trials are warranted to assess the extent of benefit. Expand
The coexistence of amyopathic dermatomyositis and fibromyalgia.
  • P. Thune
  • Medicine
  • Acta dermato-venereologica
  • 2000
TLDR
One or two pathognomonic signs associated with one or more characteristic signs and a compatible skin biopsy are required for the diagnosis of Amyopathic dermatomyositis (ADM). Expand
A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
TLDR
A systematic review of the published literature on adult-onset CADM suggests that the CADM subphenotype is more common than has been thought previously and that such patients may comprise a relatively high proportion of DM patients followed by dermatologists. Expand
Treatment of dermatomyositis with methotrexate.
TLDR
Although methotrexate is an effective treatment for dermatomyositis, side effects are common and patients with diabetes mellitus should be closely monitored for toxic effects on the liver. Expand
Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.
TLDR
Larger population-based studies are needed to estimate the risk of malignancy associated with subtypes of dermatomyositis, particularly clinically amyopathic dermatomyposis. Expand
Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?
TLDR
Significantly different prognostic and therapeutic implications are present in patients with dermatomyositis with normal muscle enzyme serum levels depending on the results of electromyography, muscle biopsy, and clinical observation. Expand
...
1
2
3
4
5
...